The Medication Affordability and Patent Integrity Act Threatens Innovation

The Senate Committee on Health, Education, Labor, and Pensions is considering S. 2658, the "Medication Affordability and Patent Integrity Act," a bill that supporters claim would improve transparency between the Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO). In reality, the legislation would weaken intellectual property protections, encourage more litigation, and burden federal agencies with new paperwork that could slow innovation and drug development.

The United States became the world's leading innovation economy by protecting inventors and rewarding risk-taking. S. 2658 moves in the opposite direction.

Strong Patents Drive New Discoveries

The U.S. Constitution specifically authorizes Congress to grant patents because the Founders understood that inventors need an opportunity to profit from their creations. Those protections encourage investment in new technologies, products, and medical breakthroughs.

That principle is especially important in pharmaceuticals, where developing a new medicine can take years of research and billions of dollars in investment. Patent protections help ensure innovators have a reasonable opportunity to recover those costs.

S. 2658 would create new disclosure requirements and a new defense to patent infringement claims tied to compliance with those requirements. Existing law already imposes severe penalties for intentionally withholding material information from the USPTO. Congress should be cautious about weakening patent rights to address a problem that has not been shown to be widespread.

A New Opportunity for Litigation

The bill could also increase litigation without improving affordability.

By creating a new defense to patent infringement, S. 2658 would encourage legal disputes over regulatory paperwork rather than the merits of a patent itself. That creates opportunities for costly lawsuits and procedural challenges that benefit trial lawyers while diverting resources away from research and development.

Every dollar spent on unnecessary litigation is a dollar that cannot be invested in developing new treatments and technologies.

More Bureaucracy for FDA and USPTO

The FDA and USPTO serve different purposes. The FDA evaluates whether medicines are safe and effective. The USPTO evaluates whether inventions qualify for patent protection.

S. 2658 would require additional information-sharing between the agencies, even though much of the material submitted to the FDA has little relevance to patent examination. The result could be larger workloads, more administrative costs, and slower decision-making at both agencies.

The USPTO already faces significant workloads, while the FDA is under constant pressure to review new therapies efficiently. Congress should be looking for ways to improve agency performance, not create new reporting requirements that slow it down.

The bill also raises concerns about proprietary information and trade secrets. Companies routinely provide sensitive data to the FDA with the expectation that it will remain protected. Expanding disclosure requirements creates additional risks for information that could benefit foreign competitors if mishandled.

CFE Takeaway

S. 2658 would weaken intellectual property protections, create new opportunities for litigation, and add unnecessary bureaucracy to two agencies that already have demanding missions.

Strong patent rights helped make the United States the global leader in innovation. Congress should reject the Medication Affordability and Patent Integrity Act and focus on policies that protect intellectual property, encourage investment, and speed the development of new medicines.